Latest SELLAS Life Sciences News & Updates

See the latest news and media coverage for SELLAS. We track all announcements, press releases, and industry mentions in real time, all in one place.

SELLAS Life Sciences (SELLAS)

Late-stage clinical biopharmaceutical company

Last updated Today

Latest news about SELLAS Life Sciences (SELLAS)

In short: SELLAS Life Sciences narrowed its Q2 2026 losses and approached a pivotal Phase 3 REGAL trial milestone for its leukemia treatment.

Yesterday SELLAS

Net loss for Q2 2026 was $9.6M, with cash at $138.3M. Phase 3 REGAL trial event count approaching, SLS009 enrollment at 28 patients.

May 12 SELLAS

Cash position $107.1M, REGAL trial at 78 events, SLS009 Phase 2 dosing ongoing.

March 19 SELLAS

Cash position $71.8M; net loss $26.9M; progress in GPS and SLS009 trials.

March 12 SELLAS

The randomized Phase 2 study will enroll 80 patients unlikely to benefit from standard therapy.

Yesterday Yahoo Finance

Sellas Life Sciences (SLS) reported a Q2 loss late Tuesday of $0.05 per diluted share, narrowing from a loss of $0.07 a year earlier. Two...

Yesterday Markets Insider

- Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80 th Event - ...

Yesterday Yahoo Finance

Wall Street expects no quarterly revenue and a GAAP loss of $0.04 per share, narrowing from $0.05...

August 4 Yahoo Finance

IBRX and SLS align with Big Pharma’s cancer push, fueling retail partnership and buyout speculation.

Never miss news about SELLAS

Track SELLAS and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Browse news for competitors to SELLAS and other trending companies.